ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Caladrius Biosciences Inc

Caladrius Biosciences Inc (CLBS)

0.4264
0.00
(0.00%)
종가: 16 1월 6:00AM
0.4264
0.00
( 0.00% )
시간외 거래: -

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

가격
0.4264
매수가
0.4264
매도가
0.43
거래량
-
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
market_cap
전일 종가
0.4264
개장가
-
최근 거래 시간
마지막 거래 시간
-
재정 규모
-
VWAP
-
평균 볼륨(3m)
-
발행 주식
8,150,000
배당수익률
-
주가수익률
-1.45
주당순이익(EPS)
-2.56
매출
-
순이익
-20.84M

Caladrius Biosciences Inc 정보

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the... Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its current product candidates include XOWNA, HONEDRA and CLBS201. 더 보기

섹터
Health & Allied Services,nec
산업
Insurance Carriers, Nec
웹사이트
본부
Wilmington, Delaware, USA
설립됨
2006

CLBS 최신 뉴스

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens...

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified...

Life Sciences Virtual Investor Conference Agenda Announced for September 15th

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual...

Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing...

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius’ initial...

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins...

Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

BASKING RIDGE, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company...

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CLBS - Frequently Asked Questions (FAQ)

What is the current Caladrius Biosciences share price?
The current share price of Caladrius Biosciences is US$ 0.4264
How many Caladrius Biosciences shares are in issue?
Caladrius Biosciences has 8,150,000 shares in issue
What is the market cap of Caladrius Biosciences?
The market capitalisation of Caladrius Biosciences is USD 3.48M
What is the 1 year trading range for Caladrius Biosciences share price?
Caladrius Biosciences has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Caladrius Biosciences?
The price to earnings ratio of Caladrius Biosciences is -1.45
What is the reporting currency for Caladrius Biosciences?
Caladrius Biosciences reports financial results in USD
What is the latest annual profit for Caladrius Biosciences?
The latest annual profit of Caladrius Biosciences is USD -20.84M
What is the registered address of Caladrius Biosciences?
The registered address for Caladrius Biosciences is 651 N BROAD ST SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19709
What is the Caladrius Biosciences website address?
The website address for Caladrius Biosciences is www.caladrius.com
Which industry sector does Caladrius Biosciences operate in?
Caladrius Biosciences operates in the INSURANCE CARRIERS, NEC sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
SLXNSilexion Therapeutics Corporation
US$ 2.97
(90.38%)
5.41M
PMAXPowell Max Ltd
US$ 2.4707
(78.92%)
4.27M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.2677
(15.24%)
8.85M
NVNINVNI Group Ltd
US$ 1.92
(13.61%)
77.87k
SOBRSOBR Safe Inc
US$ 0.9853
(10.71%)
1.61M
RIMEAlgorhythm Holdings Inc
US$ 0.0414
(-17.53%)
12.61M
AMIXAutonomix Medical Inc
US$ 2.6403
(-13.15%)
185.9k
PTLEPTL Ltd
US$ 3.87
(-11.03%)
79.35k
SGBXSafe and Green Holdings Corporation
US$ 0.86
(-8.99%)
686.35k
NAOVNanoVibronix Inc
US$ 0.52
(-8.77%)
246.34k
RIMEAlgorhythm Holdings Inc
US$ 0.0413
(-17.73%)
12.62M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.2677
(15.24%)
8.85M
ACONAclarion Inc
US$ 0.044
(3.53%)
5.61M
SLXNSilexion Therapeutics Corporation
US$ 2.9799
(91.02%)
5.41M
PMAXPowell Max Ltd
US$ 2.4707
(78.92%)
4.27M
tat4tat tat4tat 5 분 전
The quarter ended on Sept 30 2024. How much time do they need. Is not 3 1/2 months a bit much. They said they were DONE and waiting for green light from legal. Did they lie? Cant wait to dump my position.
CEOS
ninedoors ninedoors 5 분 전
The gist I get from reading Parrot and Zandi's impicit guarantee argument is that it's less of a counter-argument and more of a concern and acknowledgement that Trump's already going ahead with the privatization as they please.

They also acknowledge that "given their much-improved ca
FNMA
igotthemojo igotthemojo 5 분 전
That 4 year contract just expired a couple of months ago…so no, it’s not “too long ago”…

If you don’t care one way or the other, why post at all?…
KBLB
Real McCoy Real McCoy 6 분 전
It’s debunked fully because a Letter of Intent comes before the actual deal. You’ve seen the actual deal.
varjim varjim 6 분 전
https://www.otcmarkets.com/stock/ARRKF/news/Arras-Minerals-Drills-261-Metres--064-CuEq-In-First-Holes-at-Berezski-Central-Target---Elemes-Project-Kazakhstan?id=464760
ARRKF
NoMoDo NoMoDo 6 분 전
You must be new here. Been happening for a few days. Question is not why, but when will it stop. I would assume it will be very soon. And news should be out today. I would be surprised if it doesn't hit before open tomorrow. Very surprised. Kinda backs me into a corner, but that is the truth.
HMBL
RichieBoy RichieBoy 6 분 전
1jas YES AFFU is under NDA and definitely keeping a low profile. Binding means they have signed something... Here's the skinny, since they haven't CLOSED the acquisition, it's actually in there best interests to be in an NDA situation. I haven't got time to look it up , but think you'll find Quiet P
AFFU
weedtrader420 weedtrader420 7 분 전
BITCOIN Created a monster XRP
BTCUSD
freecs freecs 7 분 전
Shh Miro-bot.
HIRU
surfkast surfkast 8 분 전
Can't surf fish in Ohio. LOL
GVSI
Gmenfan Gmenfan 8 분 전
Whatever you may be drinking, snorting, ingesting, injecting into your body or any combination there of must be good stuff. Let's hope your body and mind can eventually heal from the effects. Hopefully there's a liberal detox clinic in your area!
igotthemojo igotthemojo 8 분 전
Gotta say, I agree with you 100%…it is what it is…and it was a failure…theres no doubt about it..

A contract was signed where Kblb was to provide a product and the kings would pay up to $40 mil for that product…

Kblb failed to provide any product and that contract died
KBLB
DMC8 DMC8 8 분 전
Could be either same person or sitting in the same office bashing. Nothing new…
AMRN
gitreal gitreal 9 분 전
That would be a lot of work documenting 5, maybe 6 years of promising an audit.

No audit of this sham company will EVER be completed.
BMXI
Split T Split T 9 분 전
milks duds, We hit the $100.00 that I had predicted would happen by Friday, however there are 2 Gaps according to Getn otta det. ,they are at
$92.32 and $96.55....will they play out during Pre or Post trading today or tomorrow? If not coop may drop to the $ 92.32 Gap after the market opens
COOP
Gmenfan Gmenfan 9 분 전
Please delete
ElectricJester54 ElectricJester54 10 분 전
Thank you as always for providing that. If only nothing would go up between that 0.129 and 0.27 so that we could get back into the 20s. But we still have 2 days left this week and who knows, maybe a OTCM disclosure or PR will hit the wire pre-market tomorrow and we can finally get back in that range
OTCM
ddls ddls 10 분 전
1/15/25, Buy: 137,000, Neutral: 502,500 ,Sell: 571,586.😀

10 trades: 4 sells, 3 buys, 3 neutral
BIEL
TenKay TenKay 10 분 전
As I expected…let’s ignore the man behind the curtain.

Today did not play out anywhere near what many expected because someone else was loading the ask all day and letting the hype drive the retail buyers to the ask.

That why the price was flat on huge buying volume.
HMBL
Just the facts maam Just the facts maam 10 분 전
So Mary Pao was not at JP Morgan to present. Maybe she was there as part of company shopping/partnering trip.
ANIP
Joe99999! Joe99999! 10 분 전
Usually if there is a rs, the company would announce well in advance and have share holders vote on it at a meeting. I dont know why is everyone panicking today.
IQST
Joe99999! Joe99999! 10 분 전
Usually if there is a rs, the company would announce well in advance and have share holders vote on it at a meeting. I dont know why is everyone panicking today.
IQST

최근 히스토리

Delayed Upgrade Clock